GlobalData on MSN
NeuroSense’s ALS drug cuts key biomarker in Phase IIb trial
PrimeC is now FDA-cleared to enter Phase III development in ALS, as competition in the indication intensifies with several ...
REGENXBIO Inc. (Nasdaq: RGNX) today announced the first patient has been dosed in the Phase IIb/III NAAVIGATE clinical trial of investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in ...
Clinical Trials Arena on MSN
Evommune terminates oral drug’s development in CSU
While Evommune is terminating development of the oral drug in CSU, trials in AD and migraine prophylaxis will continue.
All 63 donor-recipient pairs enrolled and treated according to protocol across multiple clinical centers Randomized, controlled Phase IIb trial ...
Zacks Investment Research on MSN
EVMN stock tanks as Phase IIb urticaria study misses primary goal
Shares of Evommune EVMN were down 40.2% yesterday after the company announced that the phase IIb study evaluating its oral ...
Combination of mitoxantrone hydrochloride liposome with cyclophosphamide, vincristine, and prednisone (CMOP) for patients with treatment-naïve peripheral T-cell lymphomas (PTCLs): Extended follow-up ...
Trevi Therapeutics (TRVI) on Thursday reported confirmation of the clearing sample size re-estimation for the Phase IIb CORAL trial in idiopathic pulmonary fibrosis patients with chronic cough, ...
All 63 donor-recipient pairs enrolled and treated according to protocol across multiple clinical centersRandomized, controlled Phase IIb trial evaluating TolerogenixX’s proprietary MIC technology, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results